Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Recce Pharmaceuticals Ltd. ( (AU:RCE) ) is now available.
Recce Pharmaceuticals Ltd. has announced the issuance of 17,857,143 fully paid ordinary shares, raising A$5.0 million as part of a recent placement. This move is aligned with the company’s ongoing efforts to fund additional clinical trials, for which they are in the process of obtaining necessary approvals, potentially enhancing their position in the pharmaceutical industry by advancing their anti-infective product pipeline.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development of new classes of synthetic anti-infectives. The company is primarily engaged in creating treatments to combat antibiotic-resistant superbugs and emerging viral pathogens, targeting a significant market need for innovative anti-infective solutions.
YTD Price Performance: -39.58%
Average Trading Volume: 210,969
Technical Sentiment Signal: Buy
Current Market Cap: A$68.9M
For detailed information about RCE stock, go to TipRanks’ Stock Analysis page.